Posted on Leave a comment

We have bad news about one of the most promising new coronavirus drugs

coronavirus vaccine

New coronavirus cases are surging yet again, and thousands of people are dying every week. But the world has come a long way since the early days of the pandemic when it comes to treatments. The virus is spreading like wildfire, as many people are failing to observe the safety measures that can reduce transmission. The more people get infected, the more people will die. But doctors are able to save more lives than before thanks to some therapies that can prevent COVID-19 complications and speed up recovery.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
  • A promising drug being developed to treat COVID-19 failed to show efficacy with severe coronavirus cases.
  • Eli Lilly announced that it has terminated a study evaluating the efficacy of the monoclonal antibody drug in hospitalized patients.
  • ”Bamlanivimab [LY-CoV555] is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease,” the company said in its announcement.
  • Lilly continues to study the drug in other trials and has already requested an emergency use authorization to treat mild to moderate cases of COVID-19.

In search of a coronavirus cure, researchers have taken one of the three possible avenues. Some came up with vaccine candidates, and a vaccine might be available to at-risk people by the end of the year. Others repurposed existing drugs for COVID-19 — remdesivir, dexamethasone, and blood thinners are examples that have shown a degree of efficacy. And others are developing brand new drugs, including a type of medicine that should work quite well against the new pathogen. Those are the monoclonal antibody drugs that act much like a very potent plasma transfusion, offering the recipient a high dose of neutralizing antibodies that should block the virus from infecting cells. Monoclonal antibodies can clear the virus or even theoretically provide temporary coronavirus immunity to healthy people. But as promising as these drugs might sound, we’ve just learned they have limitations, and they might not work in the cases that matter most.

Several companies are working on antibody drugs around the world, but two of them are better known than others. Regeneron has a two-antibody cocktail that President Trump received during his COVID-19 recovery. The company has already applied for emergency use authorization (EUA) with the FDA. Eli Lilly is the second, as the company also applied for an EUA even before Regeneron’s announcement. But Eli Lilly revealed a few days ago that it had to halt one of the clinical trials it’s conducting because of a mysterious side effect that wasn’t detailed to the press. The study was paused out of “an abundance of caution” on October 13th.

The National Institutes of Health, a sponsor of the trial, said on Monday that the antibody treatment posed no significant safety risk for patients, according to NPR. But Eli Lilly researchers concluded that the drug couldn’t help patients who are already experiencing severe COVID-19 complications. ”Bamlanivimab [the LY-CoV555 monoclonal antibody] is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease,” the company said.

Lilly combined the drug with remdesivir for this particular stage of the trial. President Trump received a similar combination of meds when he had COVID-19 a few weeks ago. However, Trump got the Regeneron cocktail first before he received the remdesivir regimen, and he also wasn’t experiencing any severe complications at the time.

This particular Lilly trial has been terminated, in what seems to be an unexpected blow for this particular COVID-19 therapy. However, we’ve seen other therapies fail in trials, including hydroxychloroquine, tocilizumab, and lopinavir/ritonavir. Most recently, the World Health Organization concluded that remdesivir can’t prevent COVID-19 deaths. But other studies show that the antiviral can be helpful if administered early in the illness. Furthermore, the plasma studies available so far also showed they could benefit patients if transfusions are rich in potent antibodies, and if they’re administered soon after hospitalization. All hope is not lost because the same might apply to Eli Lilly’s monoclonal antibody drug — it could prove to be a very effective COVID-19 therapy when administered early on.

Lilly will continue to run other trials. The company remains “confident … that bamlanivimab monotherapy may prevent progression of the disease for those earlier in the course of COVID-19.” While Lilly’s ACTIV-3 trial was halted, the various other studies might yield better results. The company already used data from a study of non-hospitalized patients with mild COVID-19 (BLAZE-1) to request EUA to treat mild to moderate illnesses in high-risk patients.

While Eli Lilly failed to prove the drug’s efficacy against severe COVID-19 cases, other monoclonal antibody studies might have different results. All the companies developing monoclonal antibody drugs for COVID-19 make use of different antibodies as well as various antibody combinations.

physician-recommended easy to use daily

Why Use D'OXYVA?

Expert say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Beyond a strong clinical evidence demonstrating massive improvements in blood and tissue oxygenation with blood flow throughout the macro-, and microcirculatory system while significantly improving heart rate variability amongst other inflammatory markers, our existing and new customers who purchase our products on our eCommerce non-prescription website continue to enjoy the amazing health benefits our noninvasive products deliver on four continents.

Experts call D’OXYVA a gamechanger.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Diabetes drug recalled over excess levels of cancer-causing agent

Heads up, consumers: A diabetes drug is facing recall because the medication contains excess levels of a cancer-causing agent, the U.S. Food and Drug Administration (FDA) announced this week.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Marksans Pharma Limited, a pharmaceutical company in India, announced an expanded recalled of its Metformin hydrochloride extended-release tablets, a drug used to help those who suffer from type 2 diabetes to lower their blood glucose levels. The recall, which was initially announced in June, was expanded on Monday to include an additional 76 unexpired lots of the medication.

An example of the recalled medication. (FDA)

“Marksans performed N-Nitrosodimethylamine (NDMA) testing of unexpired identified marketed lots and observed that NDMA content in some lots is exceeding the acceptable Daily Intake Limit (ADI) of 96ng/day, therefore, out of an abundance of caution, an additional 76 lots are being recalled,” the FDA said when announcing the recall. 

NDMA is a “probable human carcinogen,” meaning it’s a substance that can lead to cancer, per the FDA.

“NDMA is a known environmental contaminant found in water and foods, including meats, dairy products and vegetables. Marksans Pharma Limited has not received any reports of adverse events that have been related to this recall,” the FDA said.

The recall impacts metformin tablets between 500 mg and 750 mg. The tablets were sold under the brand name Time-Cap Labs, Inc., according to the announcement.

The following products have been called back:

Metformin Hydrochloride Extended-Release Tablets, USP 500mg:

90 counts: 49483-623-09

100 counts: 49483-623-01

500 counts: 49483-623-50

1000 counts: 49483-623-10

Metformin Hydrochloride Extended-Release Tablets, USP 750mg:

100 counts: 49483-624-01

The 500 mg tablets are debossed with “101” on one side and are plain on the other. The 750 mg tablets, meanwhile, are also debossed with “102” on one side and are plain on the other, per the FDA.

“Consumers taking these recalled product lots of Metformin ER Tablets should continue taking it until a doctor or pharmacist gives them a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their health care professional,” the FDA warned. The consumer “should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.”

physician-recommended easy to use daily

Why Use D'OXYVA?

D’OXYVA® (deoxyhemoglobin vasodilator) is a validated microcirculation and nerve stimulant for people suffering from the damaging effects of moderate to advanced neuropathy.

Subjects suffering from high blood sugar have reported noticeable neuropathy pain relief only minutes after the D’OXYVA solution protocol, including long-term blood sugar level improvements in just a few weeks.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Children born at high altitudes may be stunted in growth and development, study finds

Children born at 5,000 feet or more above sea level are typically smaller at birth and more likely to remain stunted than those born at lower altitudes, according to new worldwide research published Monday.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
This was true even if the children were born into “ideal-home environments” defined as having good health coverage, higher living conditions and highly educated mothers, the study found, which meant stunting was unlikely to be due to common risk factors such as poor diet and disease.
 

Growth declined as altitude grew

Children living in ideal home environments grew at rates deemed standard by the World Health Organization until they lived at around 500 meters (1,650 feet) above sea level, the study found. At that altitude and higher, children’s height-for-age scores began to decrease.
 
At levels of 1,500 meters, or approximately 5,000 feet, above sea level, children were “born at shorter length and remained on a lower growth trajectory” than children who lived in cities at lower sea levels, according to the study published Monday in JAMA Pediatrics.
Prior research has shown growing shorter and slower at higher altitudes can lead to an increased risk of cognitive deficits and metabolic developmental impairments tied to chronic diseases in later life.
 

A worldwide study

The study looked at height-for-age data for more than 950,000 children in 59 countries.
 
“More than 800 million people live at 1,500 meters above sea level or higher, with two-thirds of them in Sub-Saharan Africa, and Asia,” said study co-author Kalle Hirvonen, a senior research fellow at the International Food Policy Research Institute, in a statement.
 
However, there are a number of cities in the United States that fall above 5,000 feet, including Butte, Montana; Cheyenne, Jackson and Laramie, Wyoming; Flagstaff, Arizona; Las Vegas, Albuquerque and Santa Fe, New Mexico; Mammoth Lake, Big Bear Lake and South Lake Tahoe in California; and about 37 cities in Colorado, among others.
 
In fact, Aspen, Breckenridge and Telluride in Colorado and Santa Fe in New Mexico are all above 7,000 feet above sea level.
 

Pregnancy highest risk

The study found most of the risk was in the period leading up to and immediately after birth and may be due to lower oxygen levels at higher altitudes.
 
“Pregnancies at high-altitudes are characterized by chronic hypoxia, or an inadequate supply of oxygen, which is consistently associated with a higher risk of fetal growth restriction,” Hirvonen said.
 
It was thought that genetic adaption to residing at high altitude over multiple generations might mitigate the stunting, but the study did not show that, Hirvonen said.
 

“After birth, the growth curve for children in areas 1,500 (meters) or more above sea level was consistently lower, implying limited catch-up to growth levels of children residing in areas lower than 1,500 (meters) above sea level,” the study found.
 
The results should educate health professionals to more closely work with pregnant women to control the effects of high altitude on the fetus, the study authors said.
 
“A first step is to unravel the complex relationship linking altitude, hypoxia and fetal growth to identify effective interventions,” said study co-author Kaleab Baye director of the Center for Food Science and Nutrition in Addis Ababa, Ethiopia.
 
“If children living at altitude are, on average, more stunted than their peers at sea level, then a more significant effort to address high altitude stunting is needed,” Hirvonen said.

physician-recommended easy to use daily

Why Use D'OXYVA?

D’OXYVA® (deoxyhemoglobin vasodilator) is an over-the-counter (OTC) device, which is the first biotech solution of its kind backed by widely-established groundbreaking Nobel Prize-winning science validated to significantly improve macro-, and micro-circulation of blood flow and certain nerve activities in the body such as the autonomic nervous system, which together are widely reported to form an effective solution option for many of the most severe and widespread health conditions.

D’OXYVA has proven itself especially effective for the most at-risk and complex cases in over three dozen human studies during its nearly decade-long clinical research and real-life results in over two dozen countries.

D’OXYVA’s eight years of comprehensive clinical research conducted by the world’s foremost medical experts has demonstrated massive improvements for the autonomic nervous system, heart rate variability, and oxygen-rich blood flow in many parts of the body for patients with a variety of neurological symptoms as well as other discomforts. No major adverse or negative effects have ever been reported about D’OXYVA as of today.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Southeast Asia Detects Mutated Virus Strain Sweeping the World

Southeast Asia is facing a strain of the new coronavirus that the Philippines, which faces the region’s largest outbreak, is studying to see whether the mutation makes it more infectious. 

The strain, earlier seen in other parts of the world and called D614G, was found in a Malaysian cluster of 45 cases that started from someone who returned from India and breached his 14-day home quarantine. The Philippines detected the strain among random Covid-19 samples in the largest city of its capital region.

Share on facebook
Share on twitter
Share on email
Share on linkedin
Share on whatsapp

The mutation “is said to have a higher possibility of transmission or infectiousness, but we still don’t have enough solid evidence to say that that will happen,” Philippines’ Health Undersecretary Maria Rosario Vergeire said in a virtual briefing on Monday.

The strain has been found in many other countries and has become the predominant variant in Europe and the U.S., with the World Health Organization saying there’s no evidence the strain leads to a more severe disease. The mutation has also been detected in recent outbreaks in China.

There’s no evidence from the epidemiology that the mutation is considerably more infectious than other strains, said Benjamin Cowling, head of epidemiology and biostatistics at the University of Hong Kong. “It’s more commonly identified now than it was in the past, which suggests that it might have some kind of competitive advantage over other strains of Covid-19,” he said.

As Southeast Asian countries take various steps to prevent a resurgence while reopening limited travel, they struggle with people breaching quarantine rules after returning from overseas as well as false negative test results at borders.

The man who returned from India had tested negative when he arrived in Malaysia. He has since been sentenced to five months in prison and fined for breaching quarantine.

People’s Cooperation

“People need to be wary and take greater precautions because this strain has now been found in Malaysia,” the country’s Director-General of Health Noor Hisham Abdullah wrote in a Facebook post, saying the strain can make it 10 times more infectious without citing a study. “The people’s cooperation is very needed so that we can together break the chain of infection from any mutation.”

The strain “might be a little bit more contagious. We haven’t yet got enough evidence to evaluate that, but there’s no evidence that it’s a lot more contagious,” University of Hong Kong’s Cowling said.

Noor Hisham warned that the strain could mean existing studies on vaccines may be incomplete or ineffective against the mutation. That’s even as a paper published in Cell Press said the mutation is unlikely to have a major impact on the efficacy of vaccines currently being developed.

While Malaysia has largely managed to prevent a resurgence of the virus seen elsewhere in the world, the number of new cases found in the country has been picking up. The country reported 26 new cases on Saturday, the most since July 28.

Confirmed cases in the Philippines have surged 76% from the end of July to a total of 164,474 as of Monday. It overtook Indonesia more than a week ago to become the country with the largest outbreak in Southeast Asia.

— With assistance by Clarissa Batino, and Jason Gale

physician-recommended easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a gamechanger.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

About 47% of US adults have at least one underlying medical condition that may put them at a higher risk for severe Covid-19 outcomes, according to a new CDC report published Thursday.

Older adults and those with chronic obstructive pulmonary disease, heart disease, diabetes, chronic kidney disease, and obesity are at higher risk for severe COVID-19–associated illness.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

What is added by this report?

The median model-based estimate of the prevalence of any of five underlying medical conditions associated with increased risk for severe COVID-19–associated illness among U.S. adults was 47.2% among 3,142 U.S. counties. The estimated number of persons with these conditions followed population distributions, but prevalence was higher in more rural counties.

What are the implications for public health practice?

The findings can help local decision-makers identify areas at higher risk for severe COVID-19 illness in their jurisdictions and guide resource allocation and implementation of community mitigation strategies.

Risk for severe coronavirus disease 2019 (COVID-19)–associated illness (illness requiring hospitalization, intensive care unit [ICU] admission, mechanical ventilation, or resulting in death) increases with increasing age as well as presence of underlying medical conditions that have shown strong and consistent evidence, including chronic obstructive pulmonary disease, cardiovascular disease, diabetes, chronic kidney disease, and obesity (14). Identifying and describing the prevalence of these conditions at the local level can help guide decision-making and efforts to prevent or control severe COVID-19–associated illness. Below state-level estimates, there is a lack of standardized publicly available data on underlying medical conditions that increase the risk for severe COVID-19–associated illness. A small area estimation approach was used to estimate county-level prevalence of selected conditions associated with severe COVID-19 disease among U.S. adults aged ≥18 years (5,6) using self-reported data from the 2018 Behavioral Risk Factor Surveillance System (BRFSS) and U.S. Census population data. The median prevalence of any underlying medical condition in residents among 3,142 counties in all 50 states and the District of Columbia (DC) was 47.2% (range = 22.0%–66.2%); counties with the highest prevalence were concentrated in the Southeast and Appalachian region. Whereas the estimated number of persons with any underlying medical condition was higher in population-dense metropolitan areas, overall prevalence was higher in rural nonmetropolitan areas. These data can provide important local-level information about the estimated number and proportion of persons with certain underlying medical conditions to help guide decisions regarding additional resource investment, and mitigation and prevention measures to slow the spread of COVID-19.

BRFSS is an annual, random-digit–dialed landline and mobile telephone survey of noninstitutionalized U.S. adults aged ≥18 years in all 50 states, DC, and U.S. territories. BRFSS collects self-reported information on selected health behaviors and conditions. Overall, 437,500 persons participated in the 2018 BRFSS survey, with a median weighted response rate of 49.9%.*

The underlying medical conditions included in these prevalence estimates were selected using the subset of the list of conditions with the strongest and most consistent evidence of association with higher risk for severe COVID-19–associated illness on CDC’s website as of June 25, 2020 (2) and for which questions on the BRFSS aligned. These included chronic obstructive pulmonary disease (COPD), heart conditions, diabetes mellitus, chronic kidney disease (CKD), and obesity (defined as body mass index [BMI] of ≥30 kg per m2). Conditions from the list of those with mixed and limited evidence§ of association with increased risk for severe COVID-19 illness were not included (2). An analysis of U.S. COVID-19 patient surveillance data found that hospitalizations were six times higher, ICU admissions five times higher, and deaths 12 times higher among patients with underlying medical conditions, compared with those without (4); however, that analysis included a narrower definition of obesity (BMI ≥40 kg per m2), and some, but not all conditions in both the strongest and most consistent evidence and mixed and limited evidence lists.

BRFSS respondents were classified as having an underlying medical condition if they answered “yes” to any of the following questions: “Have you ever been told by a doctor, nurse, or other health professional that you have COPD, emphysema, or chronic bronchitis; heart disease (angina or coronary heart disease, heart attack, or myocardial infarction); diabetes; or chronic kidney disease?” Respondent-reported height and weight were used to calculate BMI; respondents with BMI ≥30 kg per m2 were considered to have obesity. A created variable captured persons having any of these conditions.

Nationwide estimates of underlying medical conditions were weighted to adjust for survey design. For county-level prevalence, estimates of each and of any condition were generated using a multilevel regression and poststratification approach (5) for 3,142 counties in all 50 states and DC. This approach has been validated in comparison with direct BRFSS survey estimates and local surveys for multiple chronic disease measures at state and county levels (5,6). Briefly, a multilevel regression model was constructed for each outcome using individual-level age, gender, race/ethnicity,** and educational-level†† data from the 2018 BRFSS, and data on county-level percentage of the adult population living at <150% of the poverty level from the 2014–2018 American Community Survey (ACS), a survey sent to about 3.5 million addresses each month that asks about topics not included on the decennial census, including education and employment. The model parameters were applied to 2018 Census county-level population estimates by age, gender, and race/ethnicity to calculate the predicted probability of each outcome. Because the U.S. Census Bureau does not provide county-level population data for education level by age, sex, and race/ethnicity, a bootstrapping approach§§ was used to impute it. The estimated prevalence was obtained by multiplying the probability by the total population by county. Model-based estimates for any condition were validated by comparing them with the weighted direct survey estimates from counties with sample size ≥500 (213) in BRFSS; the Pearson correlation coefficient was 0.89. The county-level estimates of having any underlying medical condition were categorized into six county urban/rural classifications using CDC’s National Center for Health Statistics definitions (large central metro/city, large fringe metro/suburb, medium metro, small metro, micropolitan, noncore/rural) (7). The overall weighted direct survey estimates were conducted using SUDAAN (version 11; RTI International), and other analyses were conducted using SAS (version 9.4; SAS Institute).

The nationwide prevalence of any of the five underlying medical conditions among adults aged ≥18 years was 40.7% (95% confidence interval [CI] = 40.4%–41.0%) (Table 1). The overall weighted prevalences of these conditions were 30.9% (obesity), 11.4% (diabetes), 6.9% (COPD), 6.8% (heart disease), and 3.1% (CKD).

TABLE 1. Nationwide and model-based county-level (n = 3,142) estimates of prevalence and number of adults aged ≥18 years with selected underlying medical conditions that might increase risk for severe COVID-19–associated illness — United States, 2018Return to your place in the text
Selected underlying medical condition*Nationwide prevalence % (95% CI)Median county prevalence§ % (range)Median county no. of adults (range)
Any40.7 (40.4, 41.0)47.2 (22.0–66.2)9,743 (41–2,877,316)
Obesity (BMI ≥30 kg/m2)30.9 (30.6, 31.2)35.4 (15.2– 49.9)7,174 (25–2,097,906)
Diabetes mellitus11.4 (11.2, 11.6)12.8 (6.1–25.6)2,742 (11–952,335)
COPD6.9 (6.7, 7.0)8.9 (3.5–19.9)1,962 (7–434, 075)
Heart disease6.8 (6.7, 7.0)8.6 (3.5–15.1)1, 811 (7–434,790)
Chronic kidney disease3.1 (3.0, 3.3)3.4 (1.8–6.2)717 (3–237,766)

Abbreviations: BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019.
* Diabetes mellitus includes both type 1 and type 2 diabetes. COPD includes emphysema and chronic bronchitis. Heart disease includes angina or coronary heart disease, and heart attack or myocardial infarction.
 Weighted direct estimates from the Behavioral Risk Factor Surveillance System, 2018.
§ Prevalence and number of adults estimated for 3,142 counties using a multilevel regression and poststratification approach applied to 2018 Behavioral Risk Factor Surveillance System data.

 

Among 3,142 counties, the median estimated (modeled) county prevalence of any underlying medical condition was 47.2% (range = 22.0%–66.2%); obesity, 35.4% (range = 15.2%–49.9%); diabetes, 12.8% (range = 6.1%–25.6%); COPD, 8.9% (range = 3.5%–19.9%); heart disease, 8.6% (range = 3.5%–15.1%); and CKD, 3.4% (range = 1.8%–6.2%) (Table 1).

Counties with the highest prevalences of any condition were concentrated in Southeastern states, particularly in Alabama, Arkansas, Kentucky, Louisiana, Mississippi, Tennessee, and West Virginia, as well as some counties in Oklahoma, South Dakota, Texas, and northern Michigan, among others (Figure) (Supplementary Table, https://stacks.cdc.gov/view/cdc/90519). The estimated number of adults with any condition generally followed the population distribution, with higher estimated numbers of persons with any underlying medical conditions in more highly populated areas.

FIGUREModel-based estimates of U.S. prevalence (A) and number (B) of adults aged ≥18 years with any selected underlying medical condition,* by county — United States, 2018

The figure is map showing model-based estimates of U.S. prevalence (A) and number (B) of adults aged ≥18 years with any selected underlying medical condition, by county, in the United States, in 2018.

* Selected underlying conditions include chronic obstructive pulmonary disease, emphysema, or chronic bronchitis; heart disease (angina or coronary heart disease, heart attack, or myocardial infarction); diabetes; chronic kidney disease; or obesity (body mass index ≥30 kg/m2).

The estimated median prevalence of any condition generally increased with increasing rurality, ranging from 39.4% in large central metro counties to 48.8% in noncore counties (Table 2); the estimated median number of persons with any underlying condition ranged from 4,300 in noncore counties to 301,744 in large central metro counties.

TABLE 2. Model-based estimates of prevalence and number of persons aged ≥18 years with any select underlying medical condition, by urban/rural county classification — United States, 2018Return to your place in the text
County classification*No. of countiesMedian county prevalence % (range)Median county no. of persons (range)
Metropolitan
Large central metro6839.4 (23.9–48.1)301,744 (43,770–2,877,316)
Large fringe metro§36843.9 (26.4–56.9)34,221 (1,611–725,284)
Medium metro37245.5 (22.0–61.7)33,687 (659–332,209)
Small metro**35845.8 (27.8–62.2)26,683 (41–87,153)
Nonmetropolitan
Micropolitan††64147.8 (24.3–64.6)13,979 (176–59,820)
Noncore§§1,33548.8 (26.8–66.2)4,300 (47–29,469)

* Based on 2013 Urban-Rural Classification Scheme for Counties from the National Center for Health Statistics, CDC.
 Large central metro counties in metropolitan statistical areas (MSAs) of 1 million population that 1) contain the entire population of the largest principal city of the MSA, or 2) are completely contained within the largest principal city of the MSA, or 3) contain ≥250,000 residents of any principal city in the MSA.
§ Large fringe metro counties in MSA of ≥1 million population that do not qualify as large central.
 Medium metro counties in MSA of 250,000–999,999 population.
** Small metro counties are counties in MSAs of <250,000 population.
†† Micropolitan counties in MSAs.
§§ Noncore counties not in MSAs.

Discussion

Three recent studies have reported that underlying medical conditions are highly prevalent among U.S. COVID-19 patients requiring hospitalization and ICU admission (3,4,8). In this report, the median county prevalence of any of five underlying medical conditions that increase the risk for severe COVID-19–associated illness was 47.2%, and prevalences were higher in counties in the southeastern United States and in more rural counties. These county level estimates can be used together with data on hospitalizations, ICU admissions, and ventilator use among COVID-19 patients with underlying conditions when planning for mitigation efforts and additional resource investment, including hospital beds, staffing, ventilators, and other medical supplies that might be needed to treat persons with underlying medical conditions, should they become ill with COVID-19.

The percentage of the population (prevalence) and the estimated numbers of adults with underlying medical conditions provide information for planning and have implications for health care resource utilization. Areas with comparatively lower prevalences but large populations, such as metropolitan areas, might still have large numbers of persons with underlying medical conditions at increased risk for severe COVID-19 illness. Conversely, areas with smaller populations but a comparatively higher prevalence of persons with underlying medical conditions might also have substantial need for additional resources to treat severe COVID-19 illness. Health care in rural counties is often underresourced,¶¶ and rural communities might have limited access to adequate care, which could further increase risk for poor COVID-19–associated outcomes. Prevalence estimates help highlight counties with a higher relative need for resources, whereas estimates of numbers of persons with underlying medical conditions help identify overall need by county; both can help decision-makers predict resource needs and develop resource allocation plans.

The findings in this report are subject to at least five limitations. First, estimates were based on BRFSS data and subject to survey biases such as nonresponse, social desirability, and recall and knowledge of having a particular condition. Second, BRFSS data do not include all underlying medical conditions that might increase risk for severe COVID-19 illness, such as sickle cell disease, or information on organ transplant or disease severity. Third, some of the underlying medical conditions included in BRFSS might not exactly capture those conditions with the strongest and most consistent evidence such as specific heart conditions (e.g., cardiomyopathies and heart failure) or specific type of diabetes. Further, because COVID-19 is a novel disease and information regarding risk factors for severe illness is evolving, additional underlying medical conditions might be added in the future (as an example, cancer was added to the list after these analyses were conducted). Fourth, BRFSS data are collected for noninstitutionalized civilian persons and exclude populations that might be particularly vulnerable to severe COVID-19 illness, including those living in long-term care facilities and incarcerated populations, and might therefore not be representative for those groups. Finally, these estimates might be imprecise because of the multilevel regression modeling process and county-level population estimation.

These findings can be used by state and local decision-makers to help identify areas at higher risk for severe COVID-19–associated illness because of underlying medical conditions and guide resource allocation and implementation of prevention and mitigation strategies. Future analyses could include weighting the contribution of each underlying medical condition according to the risk for severe COVID-19–associated outcomes, as well as identifying and incorporating other aspects of vulnerability to both infection and severe outcomes to better estimate the number of persons at increased risk for COVID-19. These findings highlight the prevalence of underlying medical conditions at the local (county) level that are important causes of morbidity and mortality on their own and increase risk for severe COVID-19–associated illness. These findings also emphasize the importance of prevention efforts to reduce the prevalence of these underlying medical conditions and their risk factors such as smoking, unhealthy diet, and lack of physical activity.

physician-recommended easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a game changer.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Laila Ali Gives Her Tips for Eating Clean and Being Thoughtful

It’s no secret that Americans struggle with diet and lifestyle. Almost 75 percent have too few vegetables and fruits in their diet, and most eat too much sugar, fat, and salt. Living through a global pandemic isn’t making things any easier.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Laila Ali wants to inspire us all to be healthier. The daughter of legendary boxer Muhammad Ali, Laila carved out her own legend as the most successful female boxer of all time, and has since created her own lifestyle brand (lailaali.com) focused on building healthy relationships with food.

“I look at health and wellness holistically,” Ali said. “Physically, mentally, and spiritually. I can be in control of my own health by being intentional about my lifestyle choices. My routine is to eat well, exercise, pray, meditate, and practice gratitude.”

For Ali, the secret is knowing what you’re putting into your body. 

“Eating clean, NON-GMO whole foods and purchasing the highest-quality ingredients that your budget allows are big factors for wellness,” she said. “Investing in high-quality supplements and vitamins is also key.”

As a mother of two, Ali has a lot of experience encouraging her family to make healthy choices. 

“I have been focused on making sure my family was healthy way before the pandemic, but now more than ever, I remind them of why I always make it a point to make them drink smoothies, take vitamins, and eat organic NON-GMO foods,” she said. “We can feel confident in our immune systems and not be fearful because we are strong, and our bodies were created to fight sickness. 

“Fear alone can weaken your immune system. So again, being in control of your health and mindset is powerful and healing in itself.”

Ali knows everyone moves at their own speed. “I encourage everyone to think about what they can add to their daily routine as opposed to what needs to be taken away,” she said. “The less overwhelming and forceful making good wellness choices can be, the more successful and long-lasting the changes will be.”

physician-recommended easy to use daily

Why Use D'OXYVA?

Trust D’OXYVA® — the advanced solution for fast, painless, and comprehensive athletic performance and injury recovery. It promotes benefits related to significantly improved blood circulation, including significantly increased cardiac activity, physical fitness, metabolism, endurance, energy balance and a healthy weight.

D’OXYVA® delivers ultra-purified CO2, the latest non-irritating, non-toxic, and fully non-invasive skin delivery infusion technology to help lose weight, recover from injury, and improve your performance.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Covid-19 and the heart: two new studies offer insights

Since the coronavirus pandemic first began, evidence has emerged showing that Covid-19 can damage more than the lungs.

The disease caused by the novel coronavirus can harm other organs in the body — including the heart — and now two separate studies, published in the journal JAMA Cardiology on Monday, provide more insight into how Covid-19 may have a prolonged impact on heart health in those who have recovered from illness and may have caused cardiac infection in those who died.

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“We’ve understood for a few months now that Covid-19 is not only a respiratory infection but a multi-system infection,” said cardiologist Dr. Nieca Goldberg, medical director of the NYU Women’s Heart Program and senior adviser for women’s health strategy at NYU Langone Health in New York, who was not involved in either study.

“There is an acute inflammatory response, increased blood clotting and cardiac involvement. And the cardiac involvement can either be due to direct involvement of the heart muscle by the infection and its inflammatory response. It could be due to blood clots that are formed, causing an obstruction of arteries,” Goldberg said.

“Sometimes people have very fast heart rates that can, over time, weaken the heart muscle, reduce the heart muscle function. So there are multiple ways during this infection that it can involve the heart.”

 

Inflammation of the heart

One of the JAMA Cardiology studies found that, among 100 adults who recently recovered from Covid, 78% showed some type of cardiac involvement in MRI scans and 60% had ongoing inflammation in the heart.

The study included patients ages 45 to 53 who were from the University Hospital Frankfurt Covid-19 Registry in Germany. They were recruited for the study between April and June. Most of the patients — 67– recovered at home, with the severity of their illness ranging from some being asymptomatic to having moderate symptoms.

The researchers used cardiac magnetic resonance imaging, blood tests and biopsy of heart tissue. Those data were compared with a group of 50 healthy volunteers and 57 volunteers with some underlying health conditions or risk factors.

© NIAID-RML his scanning electron microscope image shows SARS-CoV-2 (yellow)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient in the U.S., emerging from the surface of cells (pink) cultured in the lab. Credit: NIAID-RML

The MRI data revealed that people infected with coronavirus had some sort of heart involvement regardless of any preexisting conditions, the severity or course of their infection, the time from their original diagnosis or the presence of any specific heart-related symptoms.

The most common heart-related abnormality in the Covid-19 patients was myocardial inflammation or abnormal inflammation of the heart muscle, which can weaken it.

This type of inflammation, also called myocarditis, is usually caused by a viral infection, Goldberg said, adding that she was not surprised by these study results.

“What they’re saying in this study is that you can identify myocardial involvement or heart involvement by magnetic resonance imaging,” Goldberg said.

The study has some limitations. More research is needed to determine whether similar findings would emerge among a larger group of patients, those younger than 18 and those currently battling coronavirus infection instead of just recovering from it.

“These findings indicate the need for ongoing investigation of the long-term cardiovascular consequences of COVID-19,” the researchers wrote.

‘This infection does not follow one path’

In the other JAMA Cardiology study, an analysis of autopsies found that coronavirus could be identified in the heart tissue of Covid-19 patients who died.

The study included data from 39 autopsy cases from Germany between April 8 and April 18. The patients, ages 78 to 89, had tested positive for Covid-19 and the researchers analyzed heart tissue from their autopsies.

The researchers found that 16 of the patients had virus in their heart tissue, but did not show signs of unusual sudden inflammation in the heart or myocarditis. It’s not clear what this means, the researchers said.

The sample of autopsy cases was small and the “elderly age of the patients might have influenced the results,” the researchers wrote. More research is needed whether similar findings would emerge among a younger group of patients.

“I think both of these studies are important,” Goldberg said.

“One pretty much shows that the MRI scan can help diagnose the myocardial injury that occurs due to Covid and it was confirmed on biopsy,” she said. “The autopsy study showed us something else that’s interesting — that you can have viral presence but not the acute inflammatory process. So this infection does not follow one path.”

‘An increasingly complex puzzle’

Both studies “add to an increasingly complex puzzle” when it comes to the novel coronavirus named SARS-CoV-2, Dr. Dave Montgomery, founding cardiologist at the PREvent Clinic in Sandy Springs, Georgia, said in an email on Tuesday.

“Taken together the studies support that SARS-CoV-2 does not have to cause clinical myocarditis in order to find the virus in large numbers and the inflammatory response in myocardial tissue. In other words, one can have no or mild symptoms of heart involvement in order to actually cause damage,” said Montgomery, who was not involved in the studies.

“Viruses in general have a way of making their way to organs that are quite remote from the original site of infection. SARS-CoV-2 is no different in this regard,” he said. “What is different is that this virus seems to preferentially affect cardiac cells and the surrounding cells. These studies suggest that the heart can be infected with no clear signs. Personally, in my practice, we have seen similar signs of inflammation, including pericardial effusions,” or fluid around the sac of the heart.

Dr. Clyde Yancy of Northwestern University Feinberg School of Medicine and Dr. Gregg Fonarow of the University of California, Los Angeles, co-authored an editorial that accompanied the two new studies in the journal JAMA Cardiology on Monday.

“We see the plot thickening and we are inclined to raise a new and very evident concern that cardiomyopathy and heart failure related to COVID-19 may potentially evolve as the natural history of this infection becomes clearer,” Yancy and Fonarow wrote in the editorial.

“We wish not to generate additional anxiety but rather to incite other investigators to carefully examine existing and prospectively collect new data in other populations to con- firm or refute these findings,” they wrote.

physician-recommended easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA effects throughout the entire body is the solution to the challenges COVID-19 poses to people with underlying medical conditions. It helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a game changer.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Local woman survived COVID-19, then hit with a nearly $50,000 medical bill

D’OXYVA can save a person from the worst effects of COVID-19 for less than 1/10th of the standard care, according to recent test results.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

“My doctor told me that he almost lost me several times. Having to be in the hospital alone without my children or family to hold my hand was terrible,” said COVID-19 survivor Joycelyn Raine.

57-year-old Joycelyn Raine survived a near-death fight with COVID-19.

“I’m just so thankful that I survived. My doctor said that I’m a miracle. He said that he thought he wouldn’t be having another conversation with you but you are a fighter. Thank God. Out of the thousands of people that had passed due to COVID. The Lord show to keep me here. I am grateful for that,” said Raine.

Raine was diagnosed with COVID-19 on April 5th. She then went to a hospital in Meridian where she spent 30 days getting treated for the virus.

“I was scared. I have faith in God but I was afraid I was dying,” said Raine.

After Raine was discharged on May 24th, she went to a rehab center where she spent an additional two months. A couple of weeks after she returned home, Raine received a $45,000 bill from the hospital

“COVID has been traumatic in my life because it put me in a terrible financial bind. Thank God for county assistance, my church family, and my family. I don’t know how I would have survived,” said Raine.

Raine said her team of supporters saved her life, and you can’t put a price on that.

Raine said her COVID-19 experience was scary and encourages everyone to wear their masks.

Doesn’t your health deserve D’OXYVA?

        BUY D’OXYVA

physician-recommended easy to use daily

Why Use D'OXYVA?

Experts say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a game changer.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.s

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Americans being blindsided by medical bills amid COVID-19 pandemic

Odds are you do, considering 61% of Americans say they have experienced these costs that could lead to financial hardship.

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

PatientRightsAdvocate.org Founder Cynthia Fisher discusses why the need for price transparency in healthcare has never been more important amid the coronavirus crisis.

physician-recommended easy to use daily

Why Use D'OXYVA?

Expert say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a gamechanger.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

physician-recommended easy to use daily

Why Use D'OXYVA?

Expert say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a gamechanger.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

How Boris Kodjoe Is Supporting Black Americans and First Responders During the Pandemic

Boris Kodjoe, the star of ABC’s “Station 19,” is focused on self-care. He loves food but not diets, and says his schedule is too busy to spend hours working out.

“Moderation is key for me,” he said, noting his diet is mostly vegetarian, with no refined sugars. His fitness plan alternates between daily 25-minute interval/resistance training and stretching/mobility routines. He plays tennis some days.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

He and his family started KOFIT, a fitness app to help people introduce healthy habits into their lives.

“In these times of COVID-19, people need support in staying fit and healthy at home,” Kodjoe said. “KOFIT’s physical and mental health tips are simple and effective, and they help out the entire family.”

Nicole Ari Parker, an actress and Kodjoe’s wife, designed performance headbands with black women in mind. Called the GymWrap, the headbands wick away sweat, keeping women’s hair fresh, even during exercise.

“With the GymWrap, women can protect their hairstyles while exercising and staying healthy, yet still be ready to go to work after working out,” Kodjoe said. “We’re hoping men and women realize that adding some healthy habits to your everyday routine will increase your quality of life, even if you start out with five minutes a day.”

Supporting Black Americans

COVID-19 is affecting black Americans at a disproportionately high rate. Kodjoe says the crisis has revealed disadvantages in the community, including pre-existing health conditions and systemic discrepancies in healthcare, education, economic opportunity, social justice, access to healthy nutrition, and more.

Kodjoe and Parker are discussing social justice and equality issues with their two children.

“Nicole and I continue to guide our children through their fears and concerns, their hopes and dreams as we address these subjects, and teach them to speak up and be a part of the solution,” Kodjoe said.

The couple has actively advocated for wearing masks during the COVID-19 pandemic. Parker’s company has been selling masks and donating many to first responders through their #HelpOurHeroes initiative.

“We were inspired by the courage and commitment essential workers and first responders exhibited right from the start, and we wanted to help,” Kodjoe said, explaining they’ve given out more than 500,000 free masks so far and plan to donate more. “Hopefully more people will understand that wearing a mask is not about your personal right but rather your personal commitment to your neighbor’s health.”

ENJOY 30% DISCOUNT ON YOUR FIRST PURCHASE! USE CODE: BORIS

        BUY D’OXYVA

physician-recommended easy to use daily

Why Use D'OXYVA?

Expert say D’OXYVA can help COVID-19 patients find relief. Preliminary medical data shows people with pre-existing conditions including diabetes may experience serious complications from COVID-19.

D’OXYVA helps by delivering transdermal ultra-purified medical gas directly to the blood stream delivering major outcomes for well over 90% of users.

Experts call D’OXYVA a gamechanger.

“Studies with D’OXYVA have shown unmatched results in noninvasive woundcare,” Dr. Michael McGlamry.

Anyone with an underlying condition should know this option is available.

Reduce unwanted doctor visits, recommended and ranked top by experts!